MAP3K7 Loss Drives Enhanced Androgen Signaling and Independently Confers Risk of Recurrence in Prostate Cancer with Joint Loss of CHD1.
Jillson LK, Rider LC, Rodrigues LU, Romero L, Karimpour-Fard A, Nieto C, Gillette C, Torkko K, Danis E, Smith EE, Nolley R, Peehl DM, Lucia MS, Costello JC, Cramer SD.
Jillson LK, et al. Among authors: smith ee.
Mol Cancer Res. 2021 Jul;19(7):1123-1136. doi: 10.1158/1541-7786.MCR-20-0913. Epub 2021 Apr 12.
Mol Cancer Res. 2021.
PMID: 33846123
Free PMC article.